Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products; Correction, 14798 [06-2841]

Download as PDF 14798 Federal Register / Vol. 71, No. 57 / Friday, March 24, 2006 / Rules and Regulations frequent and routine amendments are necessary to keep them operationally current. Therefore, this regulation—(1) is not a ‘‘significant regulatory action’’ under Executive Order 12866; (2) is not a ‘‘significant rule’’ under DOT Regulatory Policies and Procedures (44 FR 11034; February 26, 1979); and (3) does not warrant preparation of a Regulatory Evaluation as the anticipated impact is so minimal. Since this is a routine matter that will only affect air traffic procedures and air navigation, it is certified that this rule will not have a significant economic impact on a substantial number of small entities under the criteria of the Regulatory Flexibility Act. Issued in Los Angeles, California, on March 3, 2006. Stephen J. Lloyd, Acting Area Director, Western Terminal Operations. [FR Doc. 06–2880 Filed 3–23–06; 8:45 am] List of Subjects in 14 CFR Part 71 RIN 0910–AB27 Airspace, Incorporation by reference, Navigation (air). Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products; Correction Adoption of the Amendment In consideration of the foregoing, the Federal Aviation Administration amends 14 CFR part 71 as follows: PART 71—DESIGNATION OF CLASS A, CLASS B, CLASS C, CLASS D, AND CLASS E AIRSPACE AREAS; ROUTES; AND REPORTING POINTS. 1. The authority citation for 14 CFR part 71 continues to read as follows: I Authority: 49 U.S.C. 106(g), 40103, 40113, 40120; E.O. 10854, 24 FR 9565, 3 CFR, 1959– 1963 Comp., p. 389; 14 CFR 11.69. [Amended] 2. The incorporation by reference in 14 CFR 71.1 of the Federal Aviation Administration Order 7400.9 N, Airspace Designations and Reporting Points, dated September 1, 2005, and effective September 15, 2005, is amended as follows: I * * * cprice-sewell on PROD1PC66 with RULES AWP CA E5 * * * Palm Springs, CA [Modify] * VerDate Aug<31>2005 * * 15:05 Mar 23, 2006 Jkt 208001 DEPARTMENT OF HEALTH AND HUMAN SERVICES Authority: 42 U.S.C. 216, 243, 263a, 264, 271. Food and Drug Administration I 21 CFR Part 1271 Food and Drug Administration, HHS. BILLING CODE 4160–01–S DEPARTMENT OF THE TREASURY Internal Revenue Service ACTION: Correcting amendment. The Food and Drug Administration (FDA) is correcting a final rule that published in the Federal Register of May 25, 2004 (69 FR 29786). The final rule required human cell, tissue, and cellular and tissue-based product (HCT/P) establishments to screen and test cell and tissue donors for risk factors for, and clinical evidence of, relevant communicable disease agents and diseases. The document was published with an error in the codified section. This document corrects that error. SUMMARY: Effective on March 24, 2006. Paula S. McKeever, Center for Biologics Evaluation and Research (HFM–17), Food and Drug Administration, 1401 Rockville Pike, suite 200N, Rockville, MD 20852–1448, 301–827–6210. SUPPLEMENTARY INFORMATION: The final regulations that are the subject of this correction require HCT/P establishments to screen and test cell and tissue donors for risk factors for, and clinical evidence of, relevant communicable disease agents and diseases. The final regulations incorrectly list a cross-reference in 21 CFR 1271.75(d)(1). This error may prove to be misleading because it inaccurately limits a referenced provision. Therefore, the error needs to be corrected. List of Subjects in 21 CFR Part 1271 Biologics, Drugs, Human cells and tissue-based products, Medical devices, Reporting and recordkeeping requirements. PO 00000 2. Amend paragraph (d)(1) of § 1271.75 by removing ‘‘(a)(1)(i)’’ and adding in its place ‘‘(a)(1)’’. Dated: March 17, 2006. Jeffrey Shuren, Assistant Commissioner for Policy. [FR Doc. 06–2841 Filed 3–23–06; 8:45 am] [Docket No. 1997N–0484S] FOR FURTHER INFORMATION CONTACT: Palm Springs, CA (Lat. 33°49′46″ N., long. 116°30′24″ W.) That airspace extending upward from 700 feet above the surface beginning at the lat. 34°05′00″ N., long. 116°34′03″ W.; to lat. 34°08′00″ N., long. 116°30′00″ W.; to lat. 34°06′42″ N., long. 116°28′49″ W.; to lat. 34°03′00″ N., long. 116°31′00″ W.; to lat. 33°42′45″ N., long. 115°53′34″ W.; to lat. 33°26′00″ N., long. 116°09′33″ W.; to lat. 33°55′00″ N., long. 116°46′03″ W., to the point of beginning. * 1. The authority citation for part 1271 continues to read as follows: DATES: Paragraph 6005 Class E airspace areas extending upward from 700 feet or more above the surface of the earth PART 1271—HUMAN CELLS, TISSUES, AND CELLULAR AND TISSUE-BASED PRODUCTS I AGENCY: I § 71.1 BILLING CODE 4910–13–M Accordingly, 21 CFR part 1271 is corrected by making the following correcting amendment: I Frm 00004 Fmt 4700 Sfmt 4700 26 CFR Part 1 [TD 9256] RIN 1545–BD97 Revised Regulations Concerning Disclosure of Relative Values of Optional Forms of Benefit Internal Revenue Service (IRS), Treasury. ACTION: Final regulations. AGENCY: SUMMARY: This document contains final regulations under section 417(a)(3) of the Internal Revenue Code concerning content requirements applicable to explanations of qualified joint and survivor annuities and qualified preretirement survivor annuities payable under certain retirement plans. These regulations affect sponsors, administrators, participants, and beneficiaries of certain retirement plans. DATES: Effective date: These regulations are effective March 24, 2006. Applicability dates: The changes to § 1.401(a)–20, A–36, and § 1.417(a)(3)–1 apply as if they had been included in TD 9099 (68 FR 70141). The change to § 1.401(a)–20, Q&A–16, applies as if it had been included in TD 8219 (53 FR 31837). FOR FURTHER INFORMATION CONTACT: Bruce Perlin or Linda Marshall at (202) 622–6090 (not a toll-free number). SUPPLEMENTARY INFORMATION: Paperwork Reduction Act The collections of information contained in these final regulations have been previously reviewed and approved E:\FR\FM\24MRR1.SGM 24MRR1

Agencies

[Federal Register Volume 71, Number 57 (Friday, March 24, 2006)]
[Rules and Regulations]
[Page 14798]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 06-2841]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 1271

[Docket No. 1997N-0484S]
RIN 0910-AB27


Eligibility Determination for Donors of Human Cells, Tissues, and 
Cellular and Tissue-Based Products; Correction

AGENCY: Food and Drug Administration, HHS.

ACTION: Correcting amendment.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is correcting a final 
rule that published in the Federal Register of May 25, 2004 (69 FR 
29786). The final rule required human cell, tissue, and cellular and 
tissue-based product (HCT/P) establishments to screen and test cell and 
tissue donors for risk factors for, and clinical evidence of, relevant 
communicable disease agents and diseases. The document was published 
with an error in the codified section. This document corrects that 
error.

DATES: Effective on March 24, 2006.

FOR FURTHER INFORMATION CONTACT: Paula S. McKeever, Center for 
Biologics Evaluation and Research (HFM-17), Food and Drug 
Administration, 1401 Rockville Pike, suite 200N, Rockville, MD 20852-
1448, 301-827-6210.

SUPPLEMENTARY INFORMATION: The final regulations that are the subject 
of this correction require HCT/P establishments to screen and test cell 
and tissue donors for risk factors for, and clinical evidence of, 
relevant communicable disease agents and diseases. The final 
regulations incorrectly list a cross-reference in 21 CFR 1271.75(d)(1). 
This error may prove to be misleading because it inaccurately limits a 
referenced provision. Therefore, the error needs to be corrected.

List of Subjects in 21 CFR Part 1271

    Biologics, Drugs, Human cells and tissue-based products, Medical 
devices, Reporting and recordkeeping requirements.

0
Accordingly, 21 CFR part 1271 is corrected by making the following 
correcting amendment:

PART 1271--HUMAN CELLS, TISSUES, AND CELLULAR AND TISSUE-BASED 
PRODUCTS

0
1. The authority citation for part 1271 continues to read as follows:

    Authority: 42 U.S.C. 216, 243, 263a, 264, 271.

0
2. Amend paragraph (d)(1) of Sec.  1271.75 by removing ``(a)(1)(i)'' 
and adding in its place ``(a)(1)''.

    Dated: March 17, 2006.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. 06-2841 Filed 3-23-06; 8:45 am]
BILLING CODE 4160-01-S

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.